Emerg Infect Dis . Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020

[tetano]

Emerg Infect Dis


. 2021 Feb;27(2):628-631.
doi: 10.3201/eid2702.204088.
Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020

Takashi Yoshiyama, Yasuki Saito, Kunitsugu Masuda, Yoshiko Nakanishi, Yasutoshi Kido, Kazuhiro Uchimura, Satoshi Mitarai, Tadaki Suzuki, Yu Nakagama, Hiroshi Kubota, Maki Satomi, Sana Uchikoba, Makoto Ohnishi, Takaji Wakita, Seiya Kato, Katsunobu Kato

• PMID: 33496235
• DOI: 10.3201/eid2702.204088

Abstract

We used 2 commercially available antibody tests to estimate seroprevalence of severe acute respiratory syndrome coronavirus 2 infection in Japan during June 2020. Of 7,950 samples, 8 were positive by both assays. Using 2 reliable antibody tests in conjunction is an effective method for estimating seroprevalence in low prevalence settings.

Keywords: 2019 novel coronavirus disease; COVID-19; Japan; SARS-CoV-2; antibodies; antibody responses; coronavirus; coronavirus disease; diagnostics; immunology; respiratory infections; serology; seroprevalence; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.